FDA approves subcutaneous Leqembi Iqlik start treatment for BioArctic-partnered Eisai

• FDA cleared Eisai’s Leqembi Iqlik subcutaneous autoinjector for weekly initiation treatment in early Alzheimer’s, extending the BioArctic-partnered franchise.
• US launch targeted for late August 2026; approved initiation dose 500 mg weekly via two 250 mg injections.
• Leqembi Iqlik already marketed in the US for weekly maintenance dosing, enabling subcutaneous use from start through long-term treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioArctic AB published the original content used to generate this news brief via Cision (Ref. ID: 202607131755BITN____UKPR__SV_20260713-BIT-8549-0) on July 13, 2026, and is solely responsible for the information contained therein.